Halozyme Therapeutics HALO
NASDAQ HALO
$101.42 -1.56 (-1.51%)
As of: Nov 11, 2026 · 11:08 AM EST

Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2026)

Updated

Halozyme Therapeutics (HALO) posted Non-Current Deferred Tax Liability of $49.06 million for Q2 2026, up 3.2% from the prior quarter.

Analysis

Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends

At the end of FY2025, Halozyme Therapeutics' Non-Current Deferred Tax Liability came in at $42.92 million.

  • The Q2 2026 figure stands as the highest quarterly Non-Current Deferred Tax Liability in data going back to Q2 2022.
  • According to Business Quant data, Non-Current Deferred Tax Liability for the three prior quarters was $47.53 million (Q1 2026), $42.92 million (Q4 2025) and $8.22 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Halozyme Therapeutics 11.73 Bn 9.97 Bn 410.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 6.34 Mn
Jun 30, 2026 49.06 Mn
Mar 31, 2026 47.53 Mn
Dec 31, 2025 42.92 Mn
Sep 30, 2025 8.22 Mn
Sep 30, 2024 11.95 Mn
Jun 30, 2024 13.65 Mn
Sep 30, 2022 28.99 Mn
Jun 30, 2022 3.29 Mn
API Access

Halozyme Therapeutics Non-Current Deferred Tax Liability API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deferred-tax-liability&ticker=HALO&period=max&api_key=YOUR_API_KEY